### Supplementary Table 2. Subgroup analyses of the association between pretreatment PNI and OS.

| Subgroup            | Studies, n | HR, 95% CI       | P   | $\Gamma^2$, % | PH  |
|---------------------|------------|------------------|-----|---------------|-----|
| **Country**         |            |                  |     |               |     |
| China               | 5          | 3.45 (1.55–7.71) | 0.002 | 71.2         | 0.008|
| Japan               | 3          | 1.74 (1.18–2.57) | 0.005 | 0            | 0.388|
| **Sample size, n**  |            |                  |     |               |     |
| >100                | 4          | 2.96 (1.55–5.67) | 0.001 | 79.9         | 0.002|
| <100                | 4          | 1.87 (0.67–5.21) | 0.229 | 51.7         | 0.102|
| **PNI cut-off**     |            |                  |     |               |     |
| >45                 | 3          | 2.29 (0.68–7.72) | 0.181 | 89.5         | <0.001|
| ≤45                 | 5          | 2.51 (1.71–3.69) | <0.001 | 18.2        | 0.299|
| **Treatment**       |            |                  |     |               |     |
| ICI                 | 4          | 2.00 (1.39–2.88) | <0.001 | 47.5         | 0.127|
| ICI+Chemo           | 4          | 2.91 (1.17–7.22) | 0.021 | 78           | 0.003|
| **NOS**             |            |                  |     |               |     |
| 7                   | 3          | 3.00 (1.13–7.99) | 0.028 | 82.2         | 0.004|
| 8                   | 5          | 1.89 (1.30–2.73) | 0.001 | 35.1         | 0.187|

**Abbreviations:** ICI: immune checkpoint inhibitor; NOS: Newcastle- Ottawa Scale; OS: overall survival.